Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha

Transplant International

Volumn 25, Issue 9, 2012, Pages 941-947

  Hassan, Qussai ^a   Roche, Bruno ^b   Buffet, Camille ^a   Bessede, Thomas ^a   Samuel, Didier ^b   Charpentier, Bernard ^a,b   Durrbach, Antoine ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

acute rejection; chronic viral hepatitis C; interferon alpha; kidney transplantation; liver transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; CORTICOSTEROID; CYCLOSPORIN A; ERYTHROPOIETIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; RIBAVIRIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ACUTE DISEASE; ADULT; AGED; BIOPSY; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; KIDNEY TRANSPLANTATION; LIVER; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RIBAVIRIN; STEROIDS; TRANSAMINASES; TREATMENT OUTCOME;

EID: 84864705172     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01520.x     Document Type: Article

References (43)

1. Aljumah AA, et al. Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients. World J Gastroenterol 2012; 18: 55.
2. Baid S, et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74.
3. Chan TM, et al. Chronic hepatitis C after renal transplantation: treatment with alpha-interferon. Transplantation 1993; 56: 1095.
4. Durlik M, et al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998; 11: S135.
5. Kramer P, et al. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 989.
6. Magnone M, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 1068.
7. Ozgur O, et al. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10: 2104.
8. Rostaing L, et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426.
9. Rostaing L, et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512.
10. Thervet E, et al. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients: a pilot study. Transplantation 1994; 58: 625.
11. Bizollon T, et al. Pilot study of the combination of interferon alpha and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500.
12. Gotz G, et al. Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin. Transplant Proc 1998; 30: 2104.
13. Mazzaferro V, et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc 1997; 29: 519.
14. Sheiner PA, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831.
15. Creput C, et al. Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation. Am J Transplant 2003; 3: 348.
16. Katznelson S, Cecka JM,. The liver neither protects the kidney from rejection nor improves kidney graft survival after combined liver and kidney transplantation from the same donor. Transplantation 1996; 61: 1403.
17. Manns MP, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958.
18. Poynard T, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303.
19. Siebert U, Sroczynski G,. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005. 21: 55.
20. Siebert U, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425.
21. Sullivan SD, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004; 99: 1490.
22. Dumortier J, et al. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669.
23. Montalbano M, et al. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol 2007; 41: 216.
24. Van Wagner LB, et al. Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol 2009; 51: 874.
25. Caeiro F, et al. Treatment of hepatitis C virus infection in kidney transplant recipients: case report. Transplant Proc 2011; 43: 259.
26. Toth CM, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998; 66: 1254.
27. Rhodes J, Jones DH, Bleehen NM,. Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo. Clin Exp Immunol 1983; 53: 739.
28. Kamar N, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184.
29. Fontaine H, et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78: 853.
30. Kamar N, et al. Lack of evidence for ribavirin monotherapy efficacy on liver fibrosis in hepatitis C virus positive renal transplant patients. Transplantation 2005. 79: 1770; author reply 1771.
31. Opelz G, Margreiter R, Dohler B,. Prolongation of long-term kidney graft survival by a simultaneous liver transplant: the liver does it, and the heart does it too. Transplantation 2002. 74: 1390; Discussion 1370-1.
32. Beaudreuil S, et al. New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation? Transpl Immunol 2007; 17: 98.
33. Sumimoto R, Kamada N,. Specific suppression of allograft rejection by soluble class I antigen and complexes with monoclonal antibody. Transplantation 1990; 50: 678.
34. Theise ND, et al. Liver from bone marrow in humans. Hepatology 2000; 32: 11.
35. Taylor PA, Noelle RJ, Blazar BR,. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001; 193: 1311.
36. Creput C, et al. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 2003; 39: 587.
37. Creput C, et al. Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol 2003; 64: 1033.
38. Carpentier A, et al. Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. Am J Transplant 2009; 9: 2102.
39. Dharancy S, et al. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. Transplantation 2007; 83: 906.
40. Carosella ED, Dausset J, Rouas-Freiss N,. Immunotolerant functions of HLA-G. Cell Mol Life Sci 1999; 55: 327.
41. Carosella ED, et al. HLA-G: a tolerance molecule from the major histocompatibility complex. Immunol Today 1999; 20: 60.
42. Rouas-Freiss N, et al. The immunotolerance role of HLA-G. Semin Cancer Biol 1999; 9: 3.
43. Cimsit B, et al. Combined liver kidney transplantation: critical analysis of a single-center experience. Transplant Proc 2011; 43: 901.